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Since the early ‘90s when radiofrequency ablation (RFA)
was first reported for the treatment of liver tumors [1], the
number of available technologies and clinical indications
of percutaneous image-guided thermal treatments has
largely expanded [2,3]. Nevertheless, many controversial
topics still exist in several different clinical scenarios.
Accordingly, the present special issue has been dedicated to
the current most debated applications of percutaneous ther-
mal treatments.
In particular, the issue opens with the manuscript by
Tomasian and Jennings [4] who report on image-guided
thermal treatments of bone tumors, which is considered a
safe [5] minimally-invasive option to provide pain relief and
effective local tumor control in selected patients [6–8].
Mauri et al. [9] discussed the application of laser and RFA
for the treatment of benign and malignant thyroid diseases;
this clinical scenario is one of the latest explored frontiers in
image-guided thermal treatments [10,11]. Despite the rela-
tively recent introduction of these treatments for thyroid
tumors, thermal ablation is proposed as first-line treatment
in selected patients presenting benign thyroid nodules or as
an alternative to surgery in selected patients presenting with
thyroid cancer.
Two papers focus on kidney cancer. Given the large inci-
dence of small-sized kidney tumors (i.e. <4 cm, T1a) inciden-
tally detected on cross-sectional imaging and the favorable
reported data comparing surgery to thermal ablation for
small-sized tumors [12], it is becoming widely accepted to
propose thermal treatments for T1a tumors, especially in
non-surgical candidates. In this perspective, Filippiadis et al.
[13] highlight the crucial role of proper patients’ selection
and summarize the excellent results available for T1a tumors.
On the other hand, much more controversy exists about
tumors between 4 and 7 cm (i.e. T1b) [14,15]. Accordingly,
Welch et al. focus their attention to this particular set-up in
which the role of image-guided thermal treatments is not
well defined and is largely debated [16].
Another large section of this special issue is dedicated to
lung tumors. In particular, Deschamps et al. [17] discussed
thermal treatments of lung metastases. Very high rates of
local tumor control have been reported, especially when
oligo-metastatic patients presenting with small metastases
are treated [18]. Then, Palussiere et al. describe image-guided
thermal treatments in patients with primary lung tumors
[19]. In fact, although still not applied on a large scale, it has
been demonstrated that thermal ablation of T1a N0 non-
small-cell lung cancer in patients ineligible for surgery pro-
vides high rates of long-term local tumor control [20].
Furthermore, these authors show that ablation may be
offered to patients with oligoprogressive lung cancer disease
as well as in cases recurring after radiotherapy. In the end, a
combination of ablation and immunotherapy in patients with
lung cancer is presented as a promising future application
that needs further investigation.
Maiettini et al., in their paper, provide an overview of the
possible application of image-guided thermal ablations in
another controversial area of percutaneous treatments such
as pancreatic cancer [21]. These authors underline how abla-
tion is currently applied in patients with advanced pancreatic
cancer who have exhausted other therapeutic options. They
emphasize the potential role of these techniques in deter-
mining an immunomodulated response [22].
Putzer et al. discussed locoregional treatments in patients
affected by melanoma oligometastatic disease [23]. Ablative
therapies are also discussed in the neurologic field by Prada
et al., who have focused their review on movement and psy-
chiatric disorders, chronic pain, drug-resistant epilepsy, and
brain tumors [24].
As clinical applications of image-guided ablations are
expanding, it is of crucial importance to continue to innovate
the available ablation technologies. In this perspective, Ben-
David et al. [25], present a novel internally-cooled RFA elec-
trode that uses RF pulsing technology to create large, repro-
ducible, and spherical ablation zones.
In conclusion, in the present special issue, we have pre-
sented the most innovative and controversial scenarios
regarding percutaneous image-guided thermal treatments.
We hope that this issue may further stimulate researchers’
interest in this fascinating field of modern medicine, and in
this perspective, we strongly encourage submissions related
to all the presented topics. In the end, we hope that the
reading of the aforementioned papers written by the most
eminent opinion-leaders in the field may be immediately
useful for readers’ daily practice.
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